On March 29, 2012, Oracle announced that it has agreed to acquire ClearTrial, a leading provider of cloud-based Clinical Trial Operations and analytics products that make the planning, sourcing, and tracking of clinical projects and financial performance faster and more accurate. The transaction has closed.
The combination of Oracle and ClearTrial is expected to deliver the most comprehensive closed-loop clinical trial management offering from planning to payment. ClearTrial's activity-based costing solutions use embedded intelligence based on deep industry expertise to help life sciences companies manage the rising costs and increasing complexities of bringing new therapies to market. Together, Oracle expects to enable companies to significantly improve their ability to manage clinical trials across geographies, outsourcers, therapeutic areas, and trial phases resulting in a better return on their R&D capital investments.
Learn more about what the combination of Oracle and ClearTrial(PDF) will mean for our customers and partners
SUPPORT, SERVICES, AND SALES
ClearTrial customers and partners: Please use your existing contacts for support, professional services, and sales.
Oracle is currently reviewing the existing ClearTrial product roadmap and will be providing guidance to customers in accordance with Oracle's standard product communication policies. Any resulting features and timing of release of such features as determined by Oracle's review of ClearTrial's product roadmap are at the sole discretion of Oracle. All product roadmap information, whether communicated by ClearTrial or by Oracle, does not represent a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. It is intended for information purposes only, and may not be incorporated into any contract.
Cautionary Statement Regarding Forward-Looking Statements
This website contains certain forward-looking statements about Oracle and ClearTrial, including statements that involve risks and uncertainties concerning Oracle's acquisition of ClearTrial, anticipated customer benefits and general business outlook. When used on this website, the words "anticipates", "can", "will", "look forward to", "expected" and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or ClearTrial, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this presentation due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the possibility that the anticipated synergies of the combined companies may not be achieved, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business, and the possibility that Oracle or ClearTrial may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or ClearTrial. You are cautioned to not place undue reliance on forward-looking statements. Neither Oracle nor ClearTrial is under any duty to update any of the information in this website.